title: Comparative activities of milk components in reversing chronic colitis.
abstract: Inflammatory bowel disease (IBD) is a poorly understood chronic immune disorder for which there is no medical cure. Milk and colostrum are rich sources of bioactives with immunomodulatory properties. Here we compared the therapeutic effects of oral delivery of bovine milk-derived iron-saturated lactoferrin (Fe-bLF), angiogenin, osteopontin (OPN), colostrum whey protein, Modulen IBD (Nestle Healthsciences, Rhodes, Australia), and cis-9,trans-11 conjugated linoleic acid (CLA)-enriched milk fat in a mouse model of dextran sulfate-induced colitis. The CLA-enriched milk fat significantly increased mouse body weights after 24d of treatment, reduced epithelium damage, and downregulated the expression of proinflammatory cytokines and nitrous oxide. Modulen IBD most effectively decreased the clinical score at d 12, and Modulen IBD and OPN most effectively lowered the inflammatory score. Myeloperoxidase activity that denotes neutrophil infiltration was significantly lower in mice fed Modulen IBD, OPN, angiogenin, and Fe-bLF. A significant decrease in the numbers of T cells, natural killer cells, dendritic cells, and a significant decrease in cytokine expression were observed in mice fed the treatment diets compared with dextran sulfate administered mice. The Fe-bLF, CLA-enriched milk fat, and Modulen IBD inhibited intestinal angiogenesis. In summary, each of the milk components attenuated IBD in mice, but with differing effectiveness against specific disease parameters.
authors.affiliation: Department of Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1142, New Zealand; Nanomedicine-Laboratory of Immunology and Molecular Biomedical Research (NLIMBR), Centre for Molecular and Medical Research (C-MMR), School of Medicine (SoM), Faculty of Health, Deakin University, Waurn Ponds, Victoria 3217, Australia. Electronic address: jagat.kanwar@deakin.edu.au.
authors.forename: J R
authors.initials: JR
authors.lastname: Kanwar
authors.affiliation: Department of Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1142, New Zealand; Nanomedicine-Laboratory of Immunology and Molecular Biomedical Research (NLIMBR), Centre for Molecular and Medical Research (C-MMR), School of Medicine (SoM), Faculty of Health, Deakin University, Waurn Ponds, Victoria 3217, Australia.
authors.forename: R K
authors.initials: RK
authors.lastname: Kanwar
authors.affiliation: Fonterra Research Centre, Palmerston North, New Zealand.
authors.forename: S
authors.initials: S
authors.lastname: Stathopoulos
authors.affiliation: Fonterra Research Centre, Palmerston North, New Zealand.
authors.forename: N W
authors.initials: NW
authors.lastname: Haggarty
authors.affiliation: Fonterra Research Centre, Palmerston North, New Zealand.
authors.forename: A K H
authors.initials: AKH
authors.lastname: MacGibbon
authors.affiliation: Fonterra Research Centre, Palmerston North, New Zealand.
authors.forename: K P
authors.initials: KP
authors.lastname: Palmano
authors.affiliation: Nanomedicine-Laboratory of Immunology and Molecular Biomedical Research (NLIMBR), Centre for Molecular and Medical Research (C-MMR), School of Medicine (SoM), Faculty of Health, Deakin University, Waurn Ponds, Victoria 3217, Australia.
authors.forename: K
authors.initials: K
authors.lastname: Roy
authors.affiliation: Fonterra Research Centre, Palmerston North, New Zealand.
authors.forename: A
authors.initials: A
authors.lastname: Rowan
authors.affiliation: Department of Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1142, New Zealand.
authors.forename: G W
authors.initials: GW
authors.lastname: Krissansen
mesh_terms: D000818:Animals; D001315:Australia; D002908:Chronic Disease; D003092:Colitis / Q000139:chemically induced / Q000188:drug therapy*; D003126:Colostrum / Q000737:chemistry*; D016207:Cytokines / Q000378:metabolism; D003611:Dairy Products; D016264:Dextran Sulfate / Q000009:adverse effects; D004195:Disease Models, Animal; D006017:Glycolipids / Q000494:pharmacology; D006023:Glycoproteins / Q000494:pharmacology; D007781:Lactoferrin / Q000494:pharmacology; D044243:Linoleic Acids, Conjugated / Q000494:pharmacology; D066292:Lipid Droplets; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008892:Milk / Q000737:chemistry*; D008894:Milk Proteins / Q000494:pharmacology*; D009609:Nitrous Oxide / Q000378:metabolism; D053495:Osteopontin / Q000494:pharmacology; D012259:Ribonuclease, Pancreatic / Q000494:pharmacology; D000067816:Whey Proteins / Q000494:pharmacology
chemical_list: D016207:Cytokines; D006017:Glycolipids; D006023:Glycoproteins; D044243:Linoleic Acids, Conjugated; D008894:Milk Proteins; D000067816:Whey Proteins; C110367:milk fat globule; D053495:Osteopontin; D016264:Dextran Sulfate; C046366:angiogenin; D012259:Ribonuclease, Pancreatic; D007781:Lactoferrin; D009609:Nitrous Oxide
keywords: Modulen IBD; Osteopontin; angiogenin; conjugated linoleic acid; iron-saturated bovine lactoferrin (Fe-blf)